The human gut microbiome is a complex, dynamic ecosystem that profoundly influences host metabolism, immunity, and neurological function. Advances in synthetic biology and systems biotechnology have transformed our ability to engineer the gut microbiome for therapeutic, diagnostic, and preventive applications. This review provides a comprehensive analysis of current tools and strategies for microbiome engineering, spanning genetic manipulation of commensal strains, community-level synthetic consortia design, and biosensor-based microbial therapeutics. Cutting-edge methods such as CRISPR-Cas editing, modular plasmid systems, and ecological network modeling have enabled precise control over microbial function and stability. We discuss clinical applications in metabolic disorders, where engineered probiotics modulate glucose homeostasis and cholesterol metabolism; inflammatory and infectious diseases, where synthetic strains deliver anti-inflammatory molecules or competitively exclude pathogens; and neurological disorders, where microbial metabolites influence the gut–brain axis to modulate cognition and mood. Future directions highlight the convergence of artificial intelligence and multi-omics integration for predictive microbiome design, enabling personalized microbial therapeutics tailored to individual genetic and metabolic profiles. Novel technologies such as phage-based and RNA-guided microbiome editing promise precise, reversible modulation of microbial communities. However, challenges remain regarding biosafety, ecological stability, regulatory frameworks, and ethical considerations surrounding human microbiome modification. As computational, molecular, and clinical advances coalesce, engineered microbiomes are poised to become a cornerstone of precision medicine, transforming our approach to chronic disease management and health optimization through programmable living therapeutics.
Sutanto et al. (Sat,) studied this question.